Epoetin alfa (Epogen, Procrit)

Epoetin alfa (Epogen/Procrit/Retacrit) is covered only for FDA‑approved non‑oncology indications — anemia of CKD (on dialysis or not), zidovudine‑associated anemia in HIV, and to reduce allogeneic RBC transfusion for elective noncardiac/nonvascular surgery — and is not covered outside these indications. Coverage requires meeting specific hemoglobin or serum EPO thresholds, evidence of adequate iron stores or ongoing iron therapy, and documentation of relevant status/therapies (dialysis vs non‑dialysis, current zidovudine or ESA use, and surgical eligibility/non‑ability to donate autologous blood); recommended dosing regimens are provided.

"Anemia associated with chronic kidney disease (CKD) in individuals on dialysis and individuals not on dialysis"

Sign up to see full coverage criteria, indications, and limitations.